Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
SOUTH SAN FRANCISCO, Calif., May 07, 2018 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, will present at the Bank of America Merrill Lynch 2018 Health Care Conference. Sean McCarthy, D.Phil., president and chief executive officer will deliver a corporate overview on May 17, 2018, at 10:40 a.m. P.T./ 1:40 p.m. ET.
A live audio webcast of the presentation will be available through the Investors and News section of CytomX's website. An archived replay will be available for 90 days following the event.
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody therapeutic technology platform. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes cancer immunotherapies against clinically-validated targets, such as CX-072, a PD-L1-targeting Probody therapeutic, BMS-986249, a CTLA-4-targeting Probody therapeutic, CX-188, a PD-1-targeting Probody therapeutic, and first-in-class Probody drug conjugates against highly attractive targets, such as CX-2009, a CD166-targeting Probody drug conjugate and CX-2029, a CD71-targeting Probody drug conjugate, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, Pfizer and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.
CytomX Therapeutics
Christopher Keenan
VP, Investor Relations and Corporate Communications
[email protected]
650-383-0823
